03/07/2025
L-130 is a conjugated form of psilocin, while CYB003 is a deuterated form of psilocin. Lobe has achieved something unique by stabilizing the active metabolite of psilocybin (a prodrug found in some mushrooms), which is psilocin. Psilocin is typically unstable and cannot be used as an active drug. By synthesizing dozens of combinations of psilocin with other materials, we discovered that combining psilocin with Mucic acid forms a stable new material. This salt of a weak acid and weak base is called Conjugated Psilocin (CP) or L-130. It has shown to be stable for over two years and can be used as a pharmaceutical ingredient. Additionally, it has demonstrated high bioavailability and safety in clinical trial with healthy volunteers. We have filed numerous patents to protect this novel material and two patents have been issued.
CYB003 is a deuterated form of psilocin where certain hydrogen atoms are replaced with deuterium, a heavier isotope of hydrogen. Some claim that this form has enhanced stability, but the actual data supporting this has not been made public.
Lobe now has a superior form of a highly active drug candidate and is developing it to treat several unmet medical needs, including those being investigated with CYB003, but without using isotopes, which are not typically used in the pharmaceutical industry as therapeutics.
